Turnstone Biologics Corp. reports financial results for Q4 and full year 2024.

From GlobeNewswire: 2025-03-28 21:03:00

Turnstone Biologics Corp. announced its financial results for Q4 and full year 2024, with $28.9 million in cash, cash equivalents, and short-term investments as of December 31, 2024. The company presented preclinical data on its Selected TIL therapies at the 2024 SITC Annual Meeting and discontinued the TIDAL-01 clinical studies in January 2025 for strategic reasons. R&D expenses decreased to $8.2 million in Q4 2024, while G&A expenses reduced to $3.2 million. The net loss for Q4 2024 was $12.9 million. Turnstone continues to evaluate potential strategic alternatives to maximize shareholder value.



Read more at GlobeNewswire: Turnstone Biologics Corp. Reports Fourth Quarter and Full